A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

NCT03946800 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Cancer

Interventions

BIOLOGICAL: MEDI1191
BIOLOGICAL: Durvalumab

Sponsor

MedImmune LLC